TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
6.21
+0.97 (18.51%)
At close: Jun 30, 2026, 4:00 PM EDT
6.14
-0.07 (-1.13%)
After-hours: Jun 30, 2026, 6:38 PM EDT

TransCode Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
6623624
Market Cap Growth
-3.95%157.88%-16.14%-51.08%-75.07%-
Enterprise Value
-7.98129.99-3.340.580.952.92
Last Close Price
6.216.8366.084264.96348237.001397090.00
PB Ratio
3.840.61-1.201.761.831.16
P/TBV Ratio
---0.501.891.20
EV/EBITDA Ratio
--0.22---
EV/EBIT Ratio
--0.21---
EV/FCF Ratio
--0.25---
Debt / Equity Ratio
-000.0200
Net Debt / Equity Ratio
-10.26-1.722.86-1.41-1.53-1.02
Net Debt / EBITDA Ratio
0.300.640.380.120.273.41
Net Debt / FCF Ratio
0.600.910.430.130.313.77
Quick Ratio
2.395.372.100.791.238.22
Current Ratio
3.116.292.561.281.708.97
Return on Equity (ROE)
-26.93%-46.26%8866.94%-759.85%-148.57%-80.53%
Return on Assets (ROA)
-26.64%-32.76%-251.29%-304.42%-122.08%-51.27%
Return on Invested Capital (ROIC)
-30.23%-39.33%-2208.14%-2851.10%-8367.67%-2477.13%
Return on Capital Employed (ROCE)
-27.40%-34.24%-505.04%-789.40%-157.61%-58.43%
Buyback Yield / Dilution
-1515.08%-5392.22%-6382.75%-1003.39%0.00%-179.92%
Total Shareholder Return
-1515.08%-5392.22%-6382.75%-1003.39%0.00%-179.92%
SEC Filings: 10-K · 10-Q